Indian drug firms counter US 'bluff' on IPR regime
This article was originally published in SRA
Indian firms have launched a strong counter attack against Big Pharma's attempts to deride the country's intellectual property rights (IPR) regime and also thrown in an indirect challenge that they claim will call the US's 'bluff' on India's patent regulation.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.